Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease

PHASE2/PHASE3Enrolling by invitationINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 19, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

April 1, 2026

Conditions

Huntington Disease

Interventions

DRUG

Deutetrabenazine

Maximum dose of 48mg/day or up to 36 mg/d if receiving a strong CYP2D6 inhibitor

Trial Locations (1)

Vanderbilt University Medical Center, Nashville

All Listed Sponsors

collaborator

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

lead

Vanderbilt University Medical Center

OTHER